Trial · NCT05305989
Results by group93
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 93
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Duration of Response (DOR) | Belumosudil 200 mg QD | NA | 95% Confidence Interval 5.55 to NA | months | |
| Duration of Response (DOR) | Belumosudil 200 mg BID | NA | 95% Confidence Interval 5.78 to NA | months | |
| Number of Participants With a >=7 Point Reduction (7PtR) From Baseline and >=7 Point Reduction From Baseline on 2 Consecutive Post-Baseline Assessments as Assessed by Lee Symptom Scale (LSS) | Belumosudil 200 mg QD | >=7PtR From Baseline | 8 | Participants | |
| Number of Participants With a >=7 Point Reduction (7PtR) From Baseline and >=7 Point Reduction From Baseline on 2 Consecutive Post-Baseline Assessments as Assessed by Lee Symptom Scale (LSS) | Belumosudil 200 mg BID | >=7PtR From Baseline | 2 | Participants | |
| Number of Participants With a >=7 Point Reduction (7PtR) From Baseline and >=7 Point Reduction From Baseline on 2 Consecutive Post-Baseline Assessments as Assessed by Lee Symptom Scale (LSS) | Belumosudil 400 mg QD | >=7PtR From Baseline | 0 | Participants | |
| Number of Participants With a >=7 Point Reduction (7PtR) From Baseline and >=7 Point Reduction From Baseline on 2 Consecutive Post-Baseline Assessments as Assessed by Lee Symptom Scale (LSS) | Belumosudil 200 mg QD | >=7PtR From Baseline on 2 Consecutive Post-Baseline Assessment | 8 | Participants | |
| Number of Participants With a >=7 Point Reduction (7PtR) From Baseline and >=7 Point Reduction From Baseline on 2 Consecutive Post-Baseline Assessments as Assessed by Lee Symptom Scale (LSS) | Belumosudil 200 mg BID | >=7PtR From Baseline on 2 Consecutive Post-Baseline Assessment | 1 | Participants | |
| Number of Participants With a >=7 Point Reduction (7PtR) From Baseline and >=7 Point Reduction From Baseline on 2 Consecutive Post-Baseline Assessments as Assessed by Lee Symptom Scale (LSS) | Belumosudil 400 mg QD | >=7PtR From Baseline on 2 Consecutive Post-Baseline Assessment | 0 | Participants | |
| Duration of >=7 Point Reduction as Assessed by Lee Symptom Scale | Belumosudil 200 mg QD | 67.2 | Standard Deviation 26.8 | weeks | |
| Duration of >=7 Point Reduction as Assessed by Lee Symptom Scale | Belumosudil 200 mg BID | 49.5 | Standard Deviation 54.2 | weeks | |
| Time to Next Treatment (TTNT) | Belumosudil 200 mg QD | NA | 95% Confidence Interval NA to NA | months | |
| Time to Next Treatment (TTNT) | Belumosudil 200 mg BID | NA | 95% Confidence Interval 5.14 to NA | months | |
| Time to Next Treatment (TTNT) | Belumosudil 400 mg QD | NA | 95% Confidence Interval NA to NA | months | |
| Failure-Free Survival (FFS) | Belumosudil 200 mg QD | NA | 95% Confidence Interval NA to NA | months | |
| Failure-Free Survival (FFS) | Belumosudil 200 mg BID | NA | 95% Confidence Interval 8.80 to NA | months | |
| Failure-Free Survival (FFS) | Belumosudil 400 mg QD | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Belumosudil 200 mg QD | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Belumosudil 200 mg BID | NA | 95% Confidence Interval NA to NA | months | |
| Overall Survival (OS) | Belumosudil 400 mg QD | NA | 95% Confidence Interval NA to NA | months | |
| Percentage of Participants With Complete Response (CR) and Partial Response (PR) | Belumosudil 200 mg QD | CR | 30.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05305989/results